Catherine M Moore, Anne Ljungars, Matthew J Paul, Camilla Holst Dahl, Shirin Ahmadi, Anna Christina Adams, Lise Marie Grav, Sanne Schoffelen, Bjørn Gunnar Voldborg, Andreas Hougaard Laustsen, Julian K-C Ma
Current snakebite antivenoms are based on polyclonal animal-derived antibodies, which can neutralize snake venom toxins in envenomed victims, but which are also associated with adverse reactions. Therefore, several efforts within antivenom research aim to explore the utility of recombinant monoclonal antibodies, such as human immunoglobulin G (IgG) antibodies, which are routinely used in the clinic for other indications. In this study, the feasibility of using tobacco plants as bioreactors for expressing full-length human monoclonal IgG antibodies against snake toxins was investigated...
August 15, 2023: Toxicon: Official Journal of the International Society on Toxinology